Oncology Clinical Trials in Tacoma, WA

As of July 2026, 49 paid clinical trials are recruiting for Oncology in Tacoma, Washington. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

50 clinical trials for Oncology

·Clear filters·↓ Download CSV

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

Sites in Tacoma, Renton +209 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

Sites in Tacoma, Seattle +178 more locations

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

Sites in Tacoma, Seattle +143 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer (NSCLC)

Sites in Tacoma +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07291037·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Tacoma, Olympia +61 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Tacoma, Wenatchee +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

for Diffuse Large B-Cell Lymphoma

Drug: Rituximab

Sites in Tacoma +2 more locations

Sponsor: AstraZeneca

Sex: All·Age: 65 - 99

Code: NCT05952024·Phase 2·Recruiting·Listed Jul 2023

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

Sites in Tacoma +38 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for Breast Cancer

Drug: Durvalumab

Sites in Tacoma +32 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06103864·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Conditions in Oncology (Tacoma, WA)

Breast cancer· 12 Non-small cell lung cancer (NSCLC)· 8 Multiple myeloma· 6 Solid tumor· 6 Metastatic breast cancer· 3 Colorectal cancer· 3 Gastroesophageal junction cancer· 3 Prostate cancer· 3 Ovarian cancer· 3 Gastric cancer· 2 Esophageal cancer· 2 Metastatic prostate cancer· 2 Kidney cancer· 2 Acute myeloid leukemia (AML)· 2 Chronic lymphocytic leukemia (CLL)· 2 Leukemia (other)· 2 Melanoma· 2 Neuroblastoma· 2 Cancer (any)· 2 HER2-negative breast cancer· 1 Lung cancer· 1 Small cell lung cancer· 1 Pancreatic cancer· 1 Bladder cancer· 1 Endometrial cancer· 1 Cervical cancer· 1 Acute lymphoblastic leukemia· 1 Myelodysplastic syndromes (MDS)· 1 Myelofibrosis· 1 Myeloproliferative neoplasm· 1 Non-Hodgkin lymphoma· 1 Diffuse large B-cell lymphoma (DLBCL)· 1 Small lymphocytic lymphoma· 1 Hematologic malignancy· 1 Skin cancer· 1 Head and neck cancer· 1 Thyroid cancer· 1 Sarcoma· 1 Osteosarcoma· 1